Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Road Northwest, Washington, DC 20057, USA.
Cancer Prev Res (Phila). 2010 Apr;3(4):410-5. doi: 10.1158/1940-6207.CAPR-10-0040. Epub 2010 Mar 23.
This perspective on the report by Beatty et al. in this issue of the journal (beginning on page 438) discusses the prevention of cancer through vaccination strategies that target antigens associated with tumor promotion and progression. Such approaches were first developed for treating cancer. We address cancer vaccination in the context of a mouse model of inflammatory bowel disease expressing MUC1, an epithelial mucin aberrantly expressed during chronic inflammation and in colorectal carcinogenesis, and in a broader context that includes the potential of targeting the tumor microenvironment for immunoprevention in humans. Obstacles in developing effective cancer vaccines, including antigen selection, immunoediting, and tumor-mediated immunosuppression, are also discussed.
这篇观点文章探讨了通过针对与肿瘤促进和进展相关抗原的疫苗接种策略来预防癌症。这些方法最初是为治疗癌症而开发的。我们在表达 MUC1 的炎症性肠病小鼠模型和更广泛的背景下讨论癌症疫苗接种，其中包括针对肿瘤微环境进行免疫预防的潜力。我们还讨论了开发有效癌症疫苗所面临的障碍，包括抗原选择、免疫编辑和肿瘤介导的免疫抑制。
